Cogent Biosciences Inc   (COGT)
Other Ticker:  

Cogent Biosciences Inc

Business Description

Cogent Biosciences Inc is a biotechnology company focused on the development of precision therapies for genetically driven diseases. The company is headquartered in Cambridge, Massachusetts, and was founded in 2015 by Dr. Jeffrey A. Chodakewitz and Dr. Alan F. Ezekowitz.

Cogent Biosciences is primarily engaged in the discovery, development, and commercialization of small molecule therapeutics targeting cancer and other serious diseases. The company*s therapeutic approach is based on a deep understanding of the underlying molecular drivers of diseases, with a particular focus on target molecules and pathways that are genetically implicated in the development and progression of diseases.

One of the key areas of focus for Cogent Biosciences is the development of therapies for patients with genetically defined oncology indications. The company*s lead product candidate is PLX9486, a selective inhibitor of KIT and FLT3-ITD mutations, which are known to play a role in the development of certain types of cancer. PLX9486 has shown promising preclinical and early clinical data, demonstrating its ability to inhibit tumor growth and delay disease progression in patients harboring these mutations.

Beyond oncology, Cogent Biosciences is also actively exploring therapeutic opportunities in other disease areas driven by genetic mutations. The company has developed a proprietary drug discovery platform called KinomeCore, which leverages advanced computational and structural biology approaches to identify and develop small molecules targeting kinases, a class of proteins involved in cell signaling pathways. This platform enables the company to efficiently identify and validate novel drug targets, accelerating the development of precision therapies for various genetic diseases.

In addition to its internal pipeline, Cogent Biosciences actively seeks collaborations and partnerships with other biopharmaceutical companies and academic institutions to further advance its research and development efforts. The company aims to leverage external expertise and resources to accelerate the translation of its discoveries into novel treatments for patients.

Cogent Biosciences has a team of experienced scientists, researchers, and business professionals who are dedicated to advancing the development of precision therapies. The company has established a strong intellectual property portfolio, including patents covering its novel small molecule compounds, drug discovery platform, and methods for treating various diseases.

Overall, Cogent Biosciences Inc is a biotechnology company focused on the development of precision therapies for genetically driven diseases. With its innovative drug discovery platform and promising lead candidate, the company is well-positioned to make significant contributions to the field of precision medicine and improve patient outcomes.

View Company Supplier View Company Competition View Company Customers


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com